Jump Financial LLC Invests $538,000 in Krystal Biotech, Inc. $KRYS

Key Points

• Jump Financial LLC acquired a new stake in Krystal Biotech, purchasing 2,983 shares valued at approximately $538,000, as per their recent SEC filing.
• Several institutional investors, including Nuveen LLC and T. Rowe Price, bought into Krystal Biotech during the 1st quarter, leading to a total institutional ownership of 86.29%.
• Krystal Biotech reported $1.29 earnings per share for the quarter, exceeding expectations, with a revenue of $96.04 million compared to the consensus estimate of $95.42 million.

Jump Financial LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,983 shares of the company's stock, valued at approximately $538,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KRYS. Hsbc Holdings PLC lifted its holdings in Krystal Biotech by 195.2% in the 4th quarter. Hsbc Holdings PLC now owns 4,519 shares of the company's stock worth $718,000 after purchasing an additional 2,988 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Krystal Biotech by 12.7% during the 4th quarter. The Manufacturers Life Insurance Company now owns 35,206 shares of the company's stock worth $5,515,000 after purchasing an additional 3,981 shares during the last quarter. Northern Trust Corp lifted its position in shares of Krystal Biotech by 9.9% during the 4th quarter. Northern Trust Corp now owns 262,263 shares of the company's stock worth $41,086,000 after purchasing an additional 23,572 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its position in shares of Krystal Biotech by 17.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,604 shares of the company's stock worth $1,191,000 after purchasing an additional 1,153 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Krystal Biotech by 26.4% during the 4th quarter. Ameriprise Financial Inc. now owns 113,476 shares of the company's stock worth $17,779,000 after purchasing an additional 23,727 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the completion of the transaction, the insider directly owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. This represents a 0.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders sold 49,800 shares of company stock valued at $7,487,943. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Trading Down 1.0%

KRYS traded down $1.53 on Thursday, hitting $148.67. 93,051 shares of the stock traded hands, compared to its average volume of 326,625. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $207.84. The firm has a market capitalization of $4.30 billion, a PE ratio of 30.37 and a beta of 0.66. The business has a fifty day moving average price of $146.28 and a two-hundred day moving average price of $154.21.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on KRYS. Chardan Capital cut their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research report on Friday, August 22nd. Citigroup reissued a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Friday, August 22nd. Guggenheim cut their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Bank of America cut their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $210.38.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).